Structural Formula Vector Image
Title: Interferon-b
Additional Names: Beta-interferon; fibroblast interferon; FIF; IFN-b; IFN-b1
Literature References: Cytokine with antiviral, antiproliferative and immunomodulatory activity produced by fibroblasts in response to stimulation by live or inactivated virus or by certain synthetic polynucleotides. One of the type I interferons. Glycoprotein containing 166 amino acids; mol wt ~20 kDa. Production by human fibroblast cell cultures: E. A. Havell, J. Vilcek, Antimicrob. Agents Chemother. 2, 476 (1972). Purification and initial characterization: E. Knight, Jr., Proc. Natl. Acad. Sci. USA 73, 520 (1976). Amino acid analysis, partial sequence: idem et al., Science 207, 525 (1980); S. Stein et al., Proc. Natl. Acad. Sci. USA 77, 5716 (1980). Production by recombinant DNA technology: T. Taniguchi et al., Proc. Natl. Acad. Sci. USA 77, 5230 (1980); R. Derynck et al., Nature 285, 542 (1980); D. V. Goeddel et al., Nucleic Acids Res. 8, 4057 (1980). Review of therapeutic activity in viral disease and in multiple sclerosis (MS): J. J. Alam, Curr. Opin. Biotechnol. 6, 688-691 (1995).
Derivative Type: Interferon Beta (human)
Trademarks: Feron (Toray); Fiblaferon (Rentschler); Frone (Serono); Naferon (Sclavo)
Literature References: Natural interferon produced by cell cultured human fibroblasts. Clinical evaluation in MS: L. Jacobs et al., Arch. Neurol. 44, 589 (1987); in herpes simplex infections: M. Glezerman et al., Lancet 1, 150 (1988). Review of industrial prepn: M. Morandi, A. Valeri, Adv. Biochem. Eng. Biotechnol. 37, 57-72 (1988).
Derivative Type: Interferon Beta-1a
CAS Registry Number: 145258-61-3
Trademarks: Avonex (Biogen); Rebif (Serono)
Literature References: Recombinant human IFN-b produced in Chinese Hamster ovary cells. Glycoprotein consisting of 166 amino acid residues; contains ~11% carbohydrate by weight. Clinical trial in MS: L. D. Jacobs et al., Ann. Neurol. 39, 285 (1996).
Derivative Type: Interferon Beta-1b
CAS Registry Number: 145155-23-3
Additional Names: IFN-betaser
Trademarks: Betaferon (Schering AG); Betaseron (Schering AG)
Literature References: Nonglycosylated polypeptide produced in E. coli. Consists of 165 amino acid residues; mol wt ~18.5 kDa. Synthetic mutein having a serine substituted for the cysteine residue at position 17 of the native molecule. Prepn: D. F. Mark et al., Proc. Natl. Acad. Sci. USA 81, 5662 (1984). Review of clinical use in MS: D. E. Goodkin, Lancet 344, 1057-1060 (1994). Clinical pharmacokinetics: O. A. Khan et al., Neurology 46, 1639 (1996).
Therap-Cat: Antiviral; immunomodulator.
Keywords: Antiviral; Immunomodulator.

Other Monographs:
TebuconazoleN-PhenylmaleimideRutheniumPicrolonic Acid
TrastuzumabChromium CarbonylPalivizumabSulfabenz
Glyceraldehyde 3-PhosphateFarnesolBismuth NitrateCiclosidomine
Ammonium FormateAllopregnane-3β,11β,17α,20β,21-pentolEseridinePhenyltoloxamine
©2006-2023 DrugFuture->Chemical Index Database